Adhesión real al dimetilfumarato en pacientes con esclerosis múltiple remitente-recurrenteOriginal Published on 2023-01-242024-09-05 Journal: Revista de neurologia [Category] update2024, [키워드] COVID-19 dimethyl fumarate Dimetilfumarato Disease-modifying therapy DMF Esclerosis múltiple recurrente-remitente Evidencia en el mundo real Real-world evidence Relapsing-Remitting Multiple Sclerosis Tratamiento modificador de la enfermedad [DOI] 10.33588/rn.76S01.2022296 PMC 바로가기 [Article Type] Original
Immune responses to SARS-CoV-2 vaccination in multiple sclerosis: a systematic review/meta-analysis다발성 경화증에서 SARS-CoV-2 백신 접종에 대한 면역 반응: 체계적인 검토/메타 분석Review Published on 2022-08-012022-09-11 Journal: Annals of Clinical and Translational Neurology [Category] COVID19(2023년), SARS, 치료기술, [키워드] Acetate Affect Alemtuzumab anti-CD20 Antibody detection Antibody Response Antibody responses Antibody testing applied CD20 cellular response Cellular responses Cladribine demonstrated dimethyl fumarate Epidemiology fumarate Glatiramer Glatiramer acetate Google Scholar HCs healthy control immune response Immunity inactivated independent interferon Interferon-beta mAb mAbs Meta-analysis meta-analysis and systematic review monoclonal antibody MOOSE mRNA mRNA vaccine mRNA vaccines multivariate logistic regression multivariate logistic regression model Natalizumab not affect observational studies observational study Odds ratio Patient positive predict response SARS-CoV-2 infections SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV-2 vaccines searched seroconversion rate seroconversion rates sphingosine-1-phosphate systematic review T cell T cell response T-cell Response T-cell responses Teriflunomide therapy Vaccine vaccine immunity vaccine response Vaccines vector virus [DOI] 10.1002/acn3.51628 PMC 바로가기 [Article Type] Review
Long term persistence of SARS-CoV-2 humoral response in multiple sclerosis subjects다발성 경화증 환자에서 SARS-CoV-2 체액 반응의 장기간 지속Article Published on 2022-06-012022-09-11 Journal: Multiple sclerosis and related disorders [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus age anti-Spike IgG anti-spike IgG levels appearance benefit BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine BNT162b2-mRNA vaccine booster booster vaccination booster vaccinations Cladribine Cohort comparable coronavirus Coronavirus-19 dimethyl fumarate Disease modifying therapies dose eight evaluated faster fingolimod Fingolimod- Glatiramer Glatiramer acetate groups healthy control healthy controls humoral humoral immune response Humoral persistence Humoral response IgG IgG levels interferon long term mRNA vaccine Multiple multiple sclerosis Natalizumab Ocrelizumab pandemic Patient patients persistence receiving regimen respiratory SARS-CoV-2 SARS-CoV-2 BNT162b2 SARS-CoV-2 IgG SARS-COV-2 infection SARS-CoV-2 spike protein severe acute respiratory syndrome Coronavirus spike Spike protein subject subjects Teriflunomide the SARS-CoV-2 titre variants [DOI] 10.1016/j.msard.2022.103800 PMC 바로가기 [Article Type] Article
Drugs Used in the Treatment of Multiple Sclerosis During COVID-19 Pandemic: A Critical ViewpointCovid-19 Pandemic 동안 다발성 경화증 치료에 사용되는 약물 : 중요한 관점Article Published on 2022-01-012022-08-31 Journal: Current neuropharmacology [Category] SARS, 치료제, [키워드] Acetate activating acute respiratory distress acute respiratory distress syndrome Alemtuzumab analogue antiviral activity approved ARDS autoimmune disorder Autoimmune disorders caution cellular Cladribine concern COVID-19 COVID-19 infection COVID-19 pandemic cytokine Cytokine storm Defense depleting detrimental dimethyl fumarate disease Disease-modifying therapy drug early stage endothelial example fingolimod fumarate Glatiramer Glatiramer acetate health problem hyperinflammation Hyperinflammatory IFN IFNs immunomodulation interfere interferon Invasion lung Macrophage mechanisms Multiple multiple sclerosis Natalizumab neuroprotection Nrf-2 nucleotide nucleotides Ocrelizumab other organs overcome oxidative stress pathway potential risk Protective public health raised reinforcement respiratory distress risk risk-benefit ratio. Safe SARS-CoV-2 SARS-COV-2 infection sclerosis suggested syndrome Teriflunomide Treatment Viral viral replication [DOI] 10.2174/1570159X19666210330094017 PMC 바로가기 [Article Type] Article
Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey다발성 경화증 치료 및 관리에 대한 COVID-19의 영향: 유럽 다발성 경화증 치료 및 연구 위원회의 결과Article Published on 2022-01-012022-09-11 Journal: Multiple sclerosis (Houndmills, Basingstoke, Engla [Category] SARS, 치료기술, [키워드] Access to care activated adopted Alemtuzumab anti-CD20 Care CD20 changes in Cladribine Clinical practice Committee coronavirus disease Coronavirus disease-19 country COVID-19 COVID-19 emergency dimethyl fumarate disease-modifying treatment Emergency Europe European fingolimod fumarate Glatiramer Impact interferons lymphopenia management Modification Multiple multiple sclerosis Natalizumab overcome Patient promoted reported Result Safe sclerosis Spread Telemedicine Teriflunomide therapy Treatment unique with COVID-19 [DOI] 10.1177/13524585211005339 PMC 바로가기 [Article Type] Article
Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study화이자 BNT162b2 코로나19 백신 접종 후 다발성 경화증 환자의 체액성 면역 반응: 최대 6개월 단면 연구Observational Study Published on 2021-12-152022-09-12 Journal: Journal of neuroimmunology [Category] MERS, SARS, 임상, 진단, [키워드] Alemtuzumab Appropriate Cladribine COVID-19 COVID-19 vaccination COVID19 cross-sectional demonstrated dimethyl fumarate Disease modifying treatments fingolimod healthy subject healthy subjects help Humoral immunity IgG IgG antibody IgG response immune response Multiple multiple sclerosis Natalizumab Ocrelizumab Patient response Teriflunomide treated treated patients Treatment vaccination Vaccine [DOI] 10.1016/j.jneuroim.2021.577746 PMC 바로가기 [Article Type] Observational Study
Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients사르데냐 다발성 경화증 환자에서 BNT162b2 백신에 대한 체액 반응에 대한 다양한 질병 수정 요법의 효과Immunology Published on 2021-12-092022-09-11 Journal: Frontiers in Immunology [Category] SARS, 진단, 치료법, [키워드] Acetate addition affected age Alemtuzumab analyzed anti-SARS-CoV-2 vaccine Antibody titer Antibody titers BNT162b2 BNT162b2 vaccine Clinical data clinically COVID-19 COVID-19 vaccine demographic difference dimethyl fumarate Disease-modifying therapy drug Effect Factor fingolimod followed by fumarate Glatiramer healthy control humoral immune response Humoral immunity Humoral response immune response infected with SARS-CoV-2 interferon investigated linear Male sex mixed-effects model mRNA mRNA-based Multiple multiple sclerosis objective observé of BNT162b2 Older age Patient patients patients treated Prevent response Result Sardinian SARS-CoV-2 SARS-COV-2 infection sclerosis second dose sera serology Sex significantly significantly higher significantly lower smoking smoking status statistically significant difference Teriflunomide tested therapy Treatment treatment group treatment groups uninfected untreated patients vaccination Vaccine vaccine efficacy were assessed [DOI] 10.3389/fimmu.2021.781843 PMC 바로가기 [Article Type] Immunology
Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis다발성 경화증에서 COVID-19 중증도와 질병 수정 요법의 연관성41 Published on 2021-11-092022-09-12 Journal: Neurology [Category] MERS, SARS, 진단, [키워드] 95% CI 95% confidence interval Acetate adjusted adjusted odds ratio Admission admitted to ICU age Alemtuzumab analyzed artificial ventilation association Characteristics Cladribine Cohort coronavirus disease Coronavirus disease 2019 country covariate covariates COVID-19 COVID-19 cases COVID-19 severity cross-sectional design death demographic demonstrated died dimethyl fumarate disability EDSS EDSS score examined fumarate Glatiramer Glatiramer acetate higher risk Hospitalization Hospitalized ICU ICU admission immunosuppressive include increased risk indication intensive care intensive care unit interferon internal and external International Logistic regression Multiple multiple sclerosis Natalizumab objective Ocrelizumab Older age outcome outcomes Patient phenotype reflected required restriction Result risk factor rituximab scale sclerosis severe coronavirus disease severe COVID-19 severity Sex Siponimod status Stratification therapy Ventilation were assessed with COVID-19 [DOI] 10.1212/WNL.0000000000012753 PMC 바로가기 [Article Type] 41
Immunometabolism at the cornerstone of inflammaging, immunosenescence, and autoimmunity in COVID-19코로나19 염증, 면역노화, 자가면역의 초석에 있는 면역대사Review Published on 2020-12-312022-09-01 Journal: Aging (Albany NY) [Category] MERS, SARS, 바이오마커, 진단, [키워드] approach Autoimmune Autoimmunity common factor Comorbidities Comorbidity COVID-19 COVID-19 treatment dimethyl fumarate dysregulation fumarate immunometabolism immunosenescence inflammaging leads manifestation metformin occur opens Patient Prevent Rapamycin rapamycin-metformin-dimethyl fumarate risk severe COVID-19 severe disease SLE T-cell T-cell dysfunction T-cells targeting therapeutic strategy Treatment [DOI] 10.18632/aging.202422 PMC 바로가기 [Article Type] Review
Calming the (Cytokine) Storm: Dimethyl Fumarate as a Therapeutic Candidate for COVID-19Perspective Published on 2020-12-262022-10-28 Journal: Pharmaceuticals [Category] COVID-19, [키워드] Anti-inflammatory anti-oxidative approved candidate COVID-19 death dimethyl fumarate distress fumarate hospitalisation hyperinflammation immune dysregulation immunomodulatory incidence multiple sclerosis Nrf2 oxidative stress Pathogenesis Severe case severe COVID-19 Spread the cytokine storm therapeutic option Therapeutics urgency Vaccine viable treatment while [DOI] 10.3390/ph14010015 PMC 바로가기 [Article Type] Perspective